Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Pharma’s Biggest Spenders 2022 Infographic
As several of the big 11 pharma companies dialled back on acquisitions, the collective bill for M&A and R&D activities among this cohort took a dip for the second consecutive year in 2022, even as Pfizer marched on with its spending spree. Their collective expenditure – $157 billion – might be the smallest since 2018, but it's still a…
Report library
Gene Editing: Overhyped or Unstoppable Tide?
It’s a decade since Crispr first hit the headlines and now the first product using the approach is on the verge of approval. By pharma standards, this is breakneck speed…
Q1 2023 Round Up: And so it continues...
2022 was a rough year for much of the pharma sector, with limited M&A, IPO, and venture financing activity. With Q1 now over, are we expecting to see an improvement…
Quarter 1 Round up 2023 Infographic
Pharma has had a tough go of it over the past year, with limited M&A, IPO, and venture financing activity. As Q1 draws to a close, many are wondering if the sector is…
CROI 2023 article pack
Thanks to the forum it provides the Conference on Retroviruses and Opportunistic Infections (CROI) has helped to facilitate the accelerating progress in HIV and AIDS…
Pharma Drivers: Money for Nothing
This eBook analyses the routes biotech companies are taking to gain access to public markets. While Spacs had their moment in the sun, they are now widely perceived as a…
Orphan Drugs 2023-2028: A flattening curve?
300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by…
Orphan Drugs 2023-2023: Is the shine coming off?
After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the…
Orphan Drugs: Ready to Peak?
What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat…
PD(L)anner – February 2023
The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in…
Cardiology: the heart of the matter
This infographic gives you the vital signs of the cardiology landscape. Get a snapshot of the key medtech approvals, the industry players that are driving cardiology…
